SCHEMBL4670898

SCHEMBL4670898

O=C(O)/C(O)=C/C(=O)c1nc(Cc2ccccn2)cs1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
POLB P06746 3/20 0.37
PTPRA P18433 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
PTGER1 P34995 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ASIC3 Q9UHC3 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670896 1.00 ALDH1A1 (0.39) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4675737 0.84 PTGER1 (0.41) ALDH1A1KDM4EKMT2ASMN1; SMN2NPC1
SCHEMBL4675741 0.84 PTGER1 (0.41) ALDH1A1KDM4EKMT2ASMN1; SMN2NPC1
SCHEMBL4672369 0.80 PTGER1 (0.34) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4676279 0.80 PTGER1 (0.33) ALDH1A1KDM4EPTGER1HPGD
SCHEMBL4676282 0.80 PTGER1 (0.33) ALDH1A1KDM4EPTGER1HPGD
SCHEMBL4676495 0.79 CES1 (0.33) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4670764 0.79 HPGD (0.41) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4673108 0.79 HDAC1 (0.42) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4673105 0.79 HDAC1 (0.42) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885KDM4E 947/4885KMT2A 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.